Ovarian cancer proteomic landscape changes across different pathological stages and biomarker‑sets identified with integrative multiomics analysis
Ovarian cancer (OV) is a highly lethal gynecological malignant tumor.
A comprehensive proteomic analysis of 60 ovarian cancer (OV) tissues covering FIGO stages I‑IV and 17 benign ovarian controls was performed using data‑independent acquisition (DIA) mass spectrometry. Integration with TCGA/GTEx data and survival analysis identified 1,669 differentially abundant proteins (DAPs) with stage‑specific enrichment in cell‑cycle and extracellular‑matrix pathways. Protein‑protein interaction mapping yielded 28 hub proteins, among which SMC2 was up‑regulated in early disease and independently associated with poorer overall survival (HR = 1.31, 95 % CI 1.12‑1.55, p = 0.0011). The study provides a stage‑resolved proteomic atlas and identifies a core 28‑protein module governing cell‑cycle regulation and genomic stability, underscoring SMC2 as a potential biomarker for ovarian cancer.
Large‑scale, stage‑specific proteomic profiling identifies novel biomarkers and elucidates molecular mechanisms underlying ovarian cancer progression, offering potential targets for early diagnosis and personalized therapy.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements